Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study

Basit Öğe Kaydı
dc.authoridDemirci, Mehmet/0000-0001-9670-2426
dc.authoridErdem, Mustafa Genco/0000-0002-7783-8130
dc.authoridUnlu, Ozge/0000-0002-5411-5925
dc.authoridKocazeybek, Bekir S/0000-0003-1072-3846
dc.authorwosidKocazeybek, Bekir/D-8113-2018
dc.authorwosidDemirci, Mehmet/O-1886-2015
dc.authorwosidErdem, Mustafa Genco/S-2964-2017
dc.authorwosidUnlu, Ozge/P-5191-2018
dc.contributor.authorErdem, Mustafa Genco
dc.contributor.authorUnlu, Ozge
dc.contributor.authorBuber, Suleyman
dc.contributor.authorDemirci, Mehmet
dc.contributor.authorKocazeybek, Bekir Sami
dc.date.accessioned2024-05-19T14:46:51Z
dc.date.available2024-05-19T14:46:51Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractVaccination is an essential public health measure for preventing the spread of illness during this continuing COVID-19 epidemic. The immune response developed by the host or the continuation of the immunological response caused by vaccination is crucial since it might alter the epidemic's prognosis. In our study, we aimed to determine the titers of anti-S-RBD antibody and surrogate neutralizing antibody (snAb) formed before and after the third dose of the BNT162b2 vaccination (on the 15th, 60th, and 90th days) in healthy adults who did not have any comorbidity either with or without prior SARS-CoV-2 infection. In this longitudinal prospective study, 300 healthy persons were randomly included between January and February 2022, following two doses of BNT162b2 immunization and before a third dosage. Blood was drawn from the peripheral veins. SARS-CoV-2 NCP IgG and anti-S-RBD IgG levels were detected by the CMIA method, and a surrogate neutralizing antibody was seen by the ELISA method. Our study included 154 (51.3%) female and 146 (48.7%) male (total 300) participants. The participants' median age was 32.5 (IQR:24-38). It was discovered that 208 individuals (69.3%) had never been infected with SARS-CoV-2, whereas 92 participants (30.7%) had SARS-CoV-2 infections in the past. Anti-S-RBD IgG and nAb IH% levels increased 5.94- and 1.26-fold on day 15, 3.63- and 1.22-fold on day 60, and 2.33- and 1.26-fold on day 90 after the third BNT162b2 vaccine dosage compared to pre-vaccination values (Day 0). In addition, the decrease in anti-S-RBD IgG levels on the 60th and 90th days was significantly different in the group without prior SARS-CoV-2 infection compared to the group with past SARS-CoV-2 infection (p < 0.05). In conclusion, it was observed that prior SARS-CoV-2 infection and the third BNT162b2 vaccine dose led to a lower decrease in both nAb and anti-S-RBD IgG levels. To evaluate the vaccine's effectiveness and update immunization programs, however, it is necessary to perform multicenter, longer-term, and comprehensive investigations on healthy individuals without immune response issues, as there are still circulating variants.en_US
dc.identifier.doi10.3390/vaccines11030560
dc.identifier.issn2076-393X
dc.identifier.issue3en_US
dc.identifier.pmid36992144en_US
dc.identifier.urihttps://doi.org10.3390/vaccines11030560
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5607
dc.identifier.volume11en_US
dc.identifier.wosWOS:000958475100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofVaccinesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectSurrogate Neutralizing Antibodyen_US
dc.subjectAnti-S-Rbd Igg Titersen_US
dc.subjectThird Doseen_US
dc.subjectBnt162b2en_US
dc.titleCould Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu